Interleukin-6 (IL-6) is produced during bacterial and viral infections and by various malignant tumors. Here, we describe novel immunosuppressive properties of IL-6 in dendritic cells (DC). In the presence of GM-CSF, IL-4, and a maturation stimulus, IL-6 skewed monocyte differentiation into phenotypically mature but functionally impaired DC. In DC matured with the toll-like receptor (TLR)4 stimulus lipopolysaccharide (LPS) or other pro-inflammatory stimuli, IL-6 inhibited CCR7 chemokine receptor up-regulation. As demonstrated for LPS-stimulated DC, IL-6 impaired chemotaxis to CCR7-activating chemokines required for recruiting DC to lymphoid tissues in vivo. Moreover, IL-6 inhibited production of tumor necrosis factor-α (TNF-α) and interferon-γ inducible protein-10 (IP-10) in DC, and DC-driven allogeneic T cell proliferation in mixed lymphocyte reactions. CCR7 expression was blocked at the transcriptional level. IL-6 led to inhibition of nuclear factor-κB (NF-κB) binding activity, regulating CCR7 transcription. Neutralization experiments revealed that autocrine IL-10 partially contributed to CCR7 suppression in IL-6-treated DC. Thus IL-6, a cytokine once labeled as "proinflammatory," can mediate immunosuppressive functions, which may involve induction of the classical "anti-inflammatory" cytokine IL-10. Because IL-6 is expressed in response to various pro-inflammatory stimuli in vivo, this mechanism may contribute to down-regulating the immune response initiated by pathogens, in persistent infections or tumors.
treated mice. The anti-inflammatory properties of IL-6 were further highlighted by its capacity to induce IL-1 receptor antagonist and the release of soluble TNF receptor p55 in macrophages in vivo. From these data, it has been proposed that IL-6 may act as an anti-inflammatory and immunosuppressive cytokine ((9) and references therein).
Recently, it has been demonstrated that the development and functional maturation of DC is impaired in plasmocytoma and chronic lymphatic leukemia patients showing overproduction of IL-6 (10, 11) . DC are professional antigen-presenting cells that play a pivotal role in immune surveillance as they control the initiation and tolerization of immune responses effected by T and B cells (12, 13) . DC development from precursor cells, including monocytes, is characterized by plasticity. When monocytes encounter fibroblasts, their differentiation is switched to a macrophage-like phenotype (14) . In vitro this process can be mimicked by the addition of IL-6 to granulocyte macrophage-colony stimulating factor (GM-CSF) and IL-4 containing culture medium (14) (15) (16) , which is normally used to differentiate monocytes into DC (17, 18) . Different pro-inflammatory stimuli, including LPS, TNF, IL-1, and CD40 ligand (CD40L) interfere with this IL-6 effect (16) . After encountering such "danger" signals, DC normally undergo functional maturation. The properties of DC generated under the influence of IL-6, however, are not known to date.
Both DC development and maturation are crucially controlled by transcription factors of the nuclear factor-κB (NF-κB) family (19) . In addition, the p38 mitogen-activated protein kinase (MAPK) pathway seems to play a role for LPS-induced maturation of DC (20) . Maturation is characterized by the up-regulation of co-stimulatory molecules and a coordinated switch in chemokine receptor expression patterns (21, 22) . The induction of the chemokine receptor CCR7 (EBI1) is regarded as a crucial, integral part of the maturation process. It confers responsiveness to ELC (EBI1 ligand chemokine, MIP3β, CCL19) produced in the T cell zone of secondary lymphoid organs and secondary lymphoid tissue chemokine SLC (CCL21), which is also expressed in lymphatic endothelium of peripheral tissues. Thus, DC leave the inflamed tissue and migrate to secondary lymphoid organs where they contact and instruct naïve T cells and coordinate the primary immune response (23, 24) . CCR7 expression is regulated mainly by the transcription factor NF-κB and activator protein-1 (25, 26) . Using the inhibitor SB203580, the p38 MAPK pathway has also been implicated in LPS-mediated CCR7 up-regulation in DC (27) .
In this study we provide a novel mechanism, how IL-6 impairs functional maturation of DC. IL-6 strongly suppressed up-regulation of the chemokine receptor CCR7 during maturation via different maturation stimuli. As demonstrated in LPS-matured DC, CCR7 suppression involved autocrine IL-10 activity and correlated with inhibition of NF-κB activation and with changes in subunit composition of bound NF-κB complexes known to be relevant for functional DC maturation.
MATERIALS AND METHODS

Monocyte isolation, culture, and stimulation
Peripheral blood mononuclear cells (PBMC) were isolated from buffy coats of healthy donors (obtained from B. Gathof, University of Cologne, Germany) by density gradient centrifugation over Ficoll-Paque (Amersham Pharmacia Biotech, Freiburg, Germany). Monocytes were purified using CD14 + microbeads (Miltenyi Biotech GmbH, Bergisch Gladbach, Germany) or an adherence purification step and were cultured for 6 days in 6-well plates (Renner GmbH, Dannstadt, Germany) at a density of 1 × 10 6 cells/ml at 37°C with 5 % CO 2 . RPMI1640 (Gibco BRL, Eggenstein, Germany) was supplemented with 10% heat-inactivated fetal calf serum (FCS), 100 U/ml penicillin, 100 µg/ml streptomycin, 1 mM sodium pyruvate, and 2 mM Lalanyl-L-glutamine. Recombinant human GM-CSF (100 ng/ml, Novartis Pharma GmbH, Nürnberg, Germany) and IL-4 (5 ng/ml, PeproTech, Rocky Hill, NJ) were added to all cultures. Recombinant human IL-6 (PeproTech) was used at 100 ng/ml and added on the first day of culture, if not indicated otherwise. In some experiments the IκB kinase (IKK) inhibitor Nacetylcysteine (N-ACC; 25 mM; 28) or the NF-κB inhibitor caffeic acid phenylethyl ester (CAPE; 25 or 50 µg/ml, dissolved in DMSO; 29) were added on day 6, 1 h (N-ACC) or 2 h (CAPE) before adding a maturation stimulus. LPS (250 ng/ml, from Salmonella typhimurium, Sigma-Aldrich, Taufkirchen, Germany), poly (I:C) (200 µg/ml, Amersham Pharmacia Biotech), TNF-α (5000 U/ml) or paraformaldehyde-fixed BHK CD40L (3 × 10 6 /ml) were added on day 6. The BHK cells were prepared as described earlier (30). One or two days later the cells were harvested as indicated in the respective experiments.
Cell staining and FACS analysis
DC generated under different conditions were double-stained with anti-CD1a-FITC and anti-CD14-allophycocyanin conjugated monoclonal antibodies (mAbs, clones HI149, M5E2, BD Biosciences, Heidelberg, Germany) or stained with anti-CD40 (mAB G28-5), anti-CD80, -CD83, -CD86, -MHC-class II, -CCR7 (clones L307.4, HB15e, FUN-1 and TÜ39, 2H4, BD Biosciences), or respective isotype control mAbs. All incubations were done for 1 h at 4°C. For intracellular staining, DC were fixed in 3% paraformaldehyde for 10 min at room temperature and were incubated with anti-DC-LAMP mAb (Immunotech, Marseille, France) in permeabilization buffer (0.5% saponin and 1% FCS in PBS) for 1 h followed by staining with secondary Ab (Dianova, Hamburg, Germany). The expression of all markers was determined by flow cytometry and mean fluorescence intensities were calculated by using the CellQuest ® program (FACScan, Becton Dickinson, Mountain View, CA).
Allogeneic mixed lymphocyte reaction (MLR)
DC were isolated as described above and cultured in the presence or absence of 100 ng/ml IL-6 for 7 days. Within the last 16 h cells were treated with 250 ng/ml LPS or medium as control. Naïve T helper cells were purified by using CD4 positive and CD45R0 negative isolation kits (Dynal Biotech, Hamburg, Germany, and Miltenyi Biotech GmbH) and co-cultured in duplicates with pretreated DC at different ratios for 5 days in 96-well plates. Cells were treated with 1 mM BrdU for the last 24 h and stained with anti-BrdU-FITC Ab using the BrdU Flow Kit (BD Biosciences), as well as OKT3 mouse anti-CD3 mAb (ATCC CRL-8001) or mouse IgG 1 isotype control and allophycocyanin-conjugated secondary antibodies. The percentage of BrdU-positive CD3-stained cells was determined by flow cytometry.
Analysis of cell morphology
The cellular morphology was investigated by phase contrast microscopy (OLYMPUS 1X70, Olympus Optical Co. GmbH, Hamburg, Germany). The pictures were taken at 400× magnification using a digital camera.
Cell migration assay
On day 8, DC grown under different conditions were resuspended in RPMI1640 medium with 0.25% bovine serum albumin (Sigma). Cells (5 × 10 6 ) were added on top of a transwell culture insert with 6.5 mm diameter and 5 µm pore size (Corning Costar Corp., NY). The chemokines SLC (200 ng/ml), ELC (200 ng/ml), and stromal derived factor-1α (SDF-1α, 100 ng/ml; all from PeproTech) were added to the lower compartment of 24-well plates. The number of cells migrated to the lower chamber within 4 h was determined.
Electrophoretic mobility shift assay (EMSA)
DC cultured under different conditions were stimulated either with medium or LPS on day 6 for different time intervals. Nuclear and cytoplasmic extracts were prepared and NF-κB binding activity was determined as described in (31). Briefly, 5 µg of each nuclear extract was analyzed by EMSA with 250 pg of 32 P-labeled double-stranded 30-bp high-affinity NF-κB probe from the mouse κ light chain enhancer. DNA-protein complexes were separated by electrophoresis in a non-denaturing 4% polyacrylamide gel and visualized by autoradiography. In supershift experiments the nuclear extracts were pre-incubated with the appropriate polyclonal Abs directed against NF-κB p50 (sc-1144X), p65 (sc-372X), c-Rel (sc-70X), RelB (sc-226X) (all from Santa Cruz, Biotechnology, Santa Cruz, CA) or rabbit IgG (Sigma) for 40 min before adding the probe.
Western blot analysis
DC were resuspended in sample buffer (62 mM Tris-HCl, pH 6.8; 2% sodium dodecyl sulfate; 0.1% bromophenol blue; 50 mM dithiothreitol; 2% glycerol). Equal amounts of protein were analyzed by Western blot using phosphorylation-specific or non-phosphorylation-specific Abs directed against the p38 MAPK (New England Biolabs, Beverly, MA, #9211 and #9212) or β-actin (Chemicon, Hofheim, Germany). Antibodies directed against NF-κB p65, p50, c-Rel, RelB, and β-actin were used to investigate nuclear and cytoplasmic extracts. The ECL reagent (Roche, Mannheim, Germany) was used for detection.
RNase protection assay
Monocytes were cultured with GM-CSF and IL-4 in the absence or presence of IL-6. Immature DC were stimulated with LPS or medium on day 6 for 24 h. Total cellular RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany). Total cellular RNA (5 µg) was analyzed by using a multi-probe template set containing DNA templates for CCR7, L32, and glyceraldehyde phosphate dehydrogenase (GAPDH, BD Bioscience) according to the manufacturer's instructions. RNase-protected RNAs were separated on 5% polyacrylamide gels containing urea. Gels were dried, and autoradiograms were taken. Band intensities were determined by applying the QuantifyOne ® 1-D analysis software (BioRad Laboratories, Munich, Germany). Relative expression levels of CCR7 mRNA were quantified using GAPDH mRNA as a standard.
IL-10, TNF-α, and IP-10 ELISAs
Monocytes were cultured in GM-CSF and IL-4 either with or without IL-6 at a density of 1 × 10 6 /ml in duplicates. The supernatants were collected on Days 1, 2, 4, and 6 and were analyzed for the presence of IL-10 using the human IL-10 OptEIA TM Set (BD Bioscience, detection limit 7.8 pg/ml) according to the supplier's instruction. TNF-α and IP-10 levels were determined 24 h after the addition of LPS or medium using the TNF-α OptEIA TM Set (BD Bioscience, detection limit 7.8 pg/ml) or the DuoSet IP-10 ELISA (R&D Systems, Wiesbaden, Germany, detection limit 9.75 pg/ml), respectively.
IL-10 neutralization assay
Monocytes were cultured in GM-CSF and IL-4 either in the presence or absence of IL-6 (100 ng/ml) or IL-10 (5 ng/ml). To block endogenous or exogenously added IL-10, a neutralizing mouse anti-human IL-10 mAb (10 µg/ml, clone 23738, R&D Systems) or matched mouse isotype (IgG 2B ) control mAbs (10 µg/ml, clone 20116, R&D Systems) were added to the final concentration of 10 µg/ml each day. Forty-eight hours after stimulation with LPS or medium (on day 6), the cells were assessed for CCR7 expression.
RESULTS
Phenotypic characterization of DC under the influence of IL-6
Peripheral blood monocytes were cultured with 100 ng/ml GM-CSF and 5 ng/ml IL-4 for 8 days. As judged by flow cytometry (Fig. 1A , upper left panel), these cultures yielded typical immature DC that were more than 90% CD1a + and less than 5% CD14 + . Their plasticity to differentiate into macrophages or DC in response to IL-6 was investigated by analyzing the expression of the surface markers CD14 and CD1a typical for monocytes/macrophages or DC, respectively. Confirming previous studies, stimulation with GM-CSF and IL-4 in the presence of 100 ng/ml IL-6 (applied at the first day of culture) impaired the down-regulation of CD14 (47 % CD14 + cells) (Fig. 1A, upper middle panel) . The percentage of CD14-positive cells in IL-6-treated DC ranged from 40 to even 72% in three different donors (data not shown). IL-6 also inhibited CD1a up-regulation (64 % CD1a + cells) reflecting disturbances in DC differentiation rather than enhanced maturation, since the cells displayed an immature DC morphology (Fig. 1A , upper right panel). 22% were CD14 and CD1a double positive (Fig. 1A , upper middle panel).
Simultaneous stimulation of monocytes with IL-6 and maturation stimuli on the first day of culture was recently reported to block the effect of IL-6 on CD14 expression (16) . In vivo, monocytes might not only encounter different stimuli simultaneously but also sequentially in the tissue environment. Therefore, we applied the pro-inflammatory mediator LPS subsequently to IL-6 and investigated the impact on monocyte differentiation. Even when LPS was added late (on day 6) to the culture medium containing GM-CSF, IL-4, and IL-6, it could reduce CD14 expression to less than 5%, whereas the cells were still more than 50% CD1a positive (Fig. 1A , lower middle panel). Although IL-6 has been shown to induce morphological features of macrophages (14), LPS did not only repress macrophage surface marker expression but consistently switched the cells to a typical DC morphology. These "IL-6-DC" displayed multiple long processes (Fig. 1A , lower right panel), resembling those of LPS-matured DC, which had not been treated with IL-6 (not shown), demonstrating the plasticity of the monocyte lineage even at late time points of differentiation.
Mature DC show a characteristic expression pattern of so-called "maturation markers", including the up-regulation of the receptor CD40, MHC class II, CD83, DC-LAMP, and of the costimulatory molecules CD80 and CD86. We next studied whether or not the maturationassociated pattern of surface markers on DC changed in response to IL-6 stimulation. Cells were cultured as above in the presence or absence of 100 ng/ml IL-6 for 8 days. LPS was added on day 6. After 48 h DC were stained using different mAbs and compared for "maturation marker" expression. As demonstrated for donor 1 in Table 1 showing the MFIs of donors 2 and 3). MHC class II expression and intracellular expression levels of DC-LAMP were up-regulated in IL-6-DC of all investigated donors up to 1.6 fold and CD86 even up to 2.9-fold (Fig. 1B) . Whereas CD83 induction was not changed in IL-6-DC of 2 donors or even slightly up-regulated in the cells of 3 more donors, it was rather inhibited by IL-6 to different degrees in 11 more donors. Thus, in 5 donors CD83 upregulation was suppressed ~20-25%, in 4 donors ~40% and in 2 donors more than 50% (Fig.  3A) . Overall, the inhibition of CD83 in IL-6-DC was significant (P=0.004, two-sided) according to paired t-test.
IL-6 inhibits the chemotactic response toward SLC and ELC
Upon maturation in vivo, DC acquire the capacity to leave the peripheral tissue through lymphatic vessels and migrate to the draining lymph node where they encounter naïve T cells. We, therefore, investigated the response of IL-6-DC to the chemokines SLC and ELC. Both chemokines are involved in the lymph node homing process via CCR7 stimulation. SDF-1α, a CXCR4 ligand was used as a control. Monocytes were again cultured as detailed above in the presence or absence of 100 ng/ml IL-6 for 8 days. LPS was added on day 6. On day 8 in vitro migration assays were performed. LPS-induced migration toward SDF-1α was only slightly affected by IL-6 treatment ( Fig. 2A, right panel) . However, in IL-6-DC the migration to both SLC and ELC was strongly reduced ( Fig. 2A , left panel), reaching up to 92% inhibition of SLCinduced and 89% inhibition of ELC-induced chemotaxis in three different donors (data not shown).
IL-6 suppresses LPS-induced up-regulation of CCR7
From the chemotaxis experiments the question arose whether IL-6-DC become less responsive to the CCR7 ligands SLC and ELC due to altered receptor expression. Therefore, the influence of IL-6 on CCR7 surface expression levels was investigated. Contrasting to the other maturation markers ( Fig. 1B and Table 1 ) and CXCR4 (data not shown), CCR7 up-regulation was strongly compromised in IL-6-DC. Suppression of LPS-mediated CCR7 induction was not only observed with the standard IL-6 dose of 100 ng/ml (85% inhibition) but still with as little as 5 ng/ml (67% inhibition; Fig. 2B ). In DC of various donors the IL-6-mediated inhibition of CCR7 upregulation ranged from 53 to 100% (Fig. 3A) . In all tested donors the extent of CCR7 inhibition strongly exceeded the extent of CD83 inhibition. CCR7 was even suppressed in those donors (Donors 3-5), where CD83 was up-regulated by IL-6. However, the inhibition of the expression of both surface molecules correlated with each other (0.687 according to Pearson), which was significant (P=0.005, two-sided) on a 0.01 level.
The effect of IL-6 on CCR7 up-regulation is not restricted to TLR4-activated DC
To investigate whether IL-6-mediated suppression of CCR7 up-regulation is limited to TLR4-activated DC, other stimuli were included into this study (Fig. 3B ). DC were again cultivated for 8 days in the presence or absence of IL-6. On day 6, the TLR3 stimulus poly (I:C) (200 µg/ml), TNF-α (5000 U/ml), or CD40L (paraformaldehyde-fixed BHK CD40L cells) were added. Similar to TLR4-matured DC, CCR7 up-regulation was completely abolished in TLR3-matured DC by IL-6 (with MFIs reduced to 0). In TNF-α-matured DC more than 70% of the cells became negative for CCR7 expression by IL-6 treatment. Interestingly, in a smaller proportion (up to 25%) of these TNF-α-matured DC MFIs were even enhanced (MFI enhancement from 90 to 165), although the regulation of this subpopulation cannot be explained at present. CD40L-induced CCR7 expression levels were less affected by IL-6, with a maximum of only 40% inhibition in three different experiments. MFIs were reduced from 16 to 9.5 in the experiment shown in Fig.  3B .
IL-6 inhibits CCR7 up-regulation at the mRNA level
To further investigate the regulation of CCR7 expression, time kinetics of IL-6 stimulation were performed. Monocytes were kept in GM-CSF and IL-4 containing medium during the whole culture period. IL-6 was added at different time points of culture as indicated in Fig. 4A . Again LPS-mediated CCR7 induction was strongly impaired when IL-6 stimulation took place on the first day of culture. The IL-6 effect gradually decreased with later stimulation time points but was still present when it was added to the cultures on day 4 (57% inhibition). To investigate, whether IL-6 affected CCR7 expression at the RNA level, monocytes were stimulated as above, including IL-6 from the first day of culture. 24 h after LPS treatment cells were harvested, total RNA was prepared and investigated by RNase protection assay. CCR7-specific mRNA was detected after activation with LPS (Fig. 4B, Lanes 3 and 4) . In IL-6-treated, LPS-matured DC, CCR7 mRNA expression was strongly reduced compared with the GAPDH control.
Phosphorylation of p38 MAPK is not suppressed by IL-6
Various signaling pathways have previously been implicated in CCR7 regulation in different cell types and in DC maturation. To elucidate which cellular responses to LPS were altered by IL-6, IL-6-treated DC and controls were stimulated with LPS for different time intervals. Whole cell extracts were prepared and assessed for activation of the p38 MAPK by using phosphorylationspecific Abs. In control cells p38 MAPK was phosphorylated as early as 10 min after LPS encounter (Fig. 5, top panel) . Unexpectedly, the signal detected in IL-6-DC was even stronger than that in controls. Equal loading of the gel was controlled by re-probing the blot with an anti-β-actin mAb (Fig. 5, bottom panel) . Equal expression of the p38 kinase itself was verified by using a non-phosphorylation-specific Ab (Fig. 5, middle panel) . From this we concluded that IL-6 enhanced rather than suppressed p38 MAPK activation.
IL-6 stimulation impairs LPS-induced NF-κB binding activity
In addition to the suppression of CCR7 induction, we observed that production levels of IP-10 and TNF-α were reduced by IL-6 in LPS-stimulated DC of four different donors (Fig. 6A) . For the induction of both molecules NF-κB activity plays an important role. Similarly, NF-κB activation has been shown to be crucial for CCR7 expression in other cell types. We therefore investigated whether suppression of NF-κB induction might affect CCR7 expression also in DC. Applying the IKK-inhibitor N-ACC (28), LPS-induced NF-κB activation was strongly reduced (Fig. 6B) . Correspondingly, N-ACC potently blocked CCR7 up-regulation in the same cells (Fig.  6C ). In addition, inhibition of LPS-induced CCR7 expression was obtained with the NF-κB inhibitor CAPE (Fig. 6D) , which also blocked LPS-induced NF-κB activation in dendritic cells (data not shown).
To determine whether or not LPS-mediated NF-κB induction is negatively regulated by IL-6, cells were stimulated as above, activated with LPS for different time intervals, and nuclear extracts were analyzed for NF-κB binding activity. Remarkable changes in LPS-inducible NF-κB complexes were observed in IL-6-DC of several donors (Fig. 7A) . In normal immature DC only one NF-κB complex was found by EMSA (Complex III, Lane 1). LPS activation (day 6) led to a strong induction of NF-κB binding activity (Lanes 3, 5, and 7). LPS-stimulation did not only enhance the binding activity of Complex III but also induced another Complex II already after 1 h (Lane 3) and an additional Complex I, which was most prominent at 4 h of stimulation (Lane 7). In IL-6-DC, the NF-κB binding patterns were strongly disturbed. Without LPS treatment a novel complex appeared (Complex IV, Lane 2). At early time points, LPS stimulation led to an increase of Complex IV in most donors (Lanes 4, 6, 12, and 14), whereas Complex II signals were hardly visible at any time point (Lanes 4, 6, 8, 10, 12, and 14) . Moreover, in IL-6-DC LPS failed to induce Complex I, and Complex III was less activated compared with the control. This became apparent already after 2 h for Donors 2-4 (Lanes 10, 12, and 14) and at later time points for all donors tested (Lane 8 and data not shown). Supershift analyses were used to identify the composition of these NF-κB complexes after 2 and 4 h of LPS stimulation (Fig. 7B) . Complex I was found to contain the RelB subunit (bottom panels, Lane 9), Complex II c-Rel (Lane 11), Complex III p65 (Lanes 5 and 6) and p50, whereas Complex IV consisted only of the p50 subunit (Lanes 7 and 8). Thus, at early time points IL-6-DC supported the induction of the transcriptionally inactive p50-p50 homodimers. Later, IL-6 strongly suppressed the formation of active NF-κB p65 homo-and heterodimers and almost completely prevented the formation of cRel and RelB NF-κB complexes. As judged from Western blot analysis of nuclear and cytoplasmic extracts (Fig. 7C) nuclear p65, p50 , and c-Rel were reduced by IL-6 stimulation, whereas nuclear RelB was not suppressed. This indicated that in the case of RelB, IL-6 only lead to inhibition of its DNA binding. In the case of p65 and c-Rel, in addition, inhibition of nuclear translocation might have contributed to the lower binding observed in Fig. 7B .
Endogenous IL-10 partially contributes to CCR7 suppression in IL-6-DC
Suppression of the NF-κB binding activity was reminiscent of the effects of IL-10. We determined IL-10 levels in supernatants of control DC and IL-6-DC at various time points. Immature control DC did not produce any detectable IL-10.
When DC were cultured in the presence of IL-6 from the first day of culture, IL-10 was present in the culture supernatants at low levels at day 2 and at higher levels (~2 ng/ml) at day 6 of culture ( Fig. 8A) . To test, whether this endogenous IL-10 played a role in IL-6-mediated CCR7 regulation, neutralization experiments were performed. Neutralizing anti-IL-10 mAbs (10 µg/ml) reversed the inhibitory IL-6 effect from 67 to 39.8% as calculated from the corresponding MFIs (Fig. 8B) . In control experiments the neutralizing mAbs completely blocked CCR7 suppression mediated by 5 ng/ml of exogenous IL-10 applied from the first day of culture. Thus, effects of an IL-10 dose higher than that produced after IL-6 stimulation were completely neutralized, whereas the IL-6 effect itself was partially blocked. When DC were treated with IL-6 from day 4 only, no IL-10 was detectable (data not shown), although CCR7 was still suppressed (Fig. 4A ).
IL-6-conditioned DC display reduced allogeneic T helper cell stimulation capacity
Since IL-6 profoundly altered the reactivity of DC by inducing IL-10 and suppression of the central transcription factor NF-κB, it was tested whether IL-6 also impaired the capacity of DC to activate T cell responses. MLRs were performed with DC pretreated with medium or IL-6 followed by activation with LPS vs. medium for 16 h. After 5 days of co-culture with naïve allogeneic responder T helper lymphocytes, BrdU incorporation of the T cell fraction was measured. As shown in Fig. 9 , IL-6 strongly suppressed the capacity of DC to induce allogeneic T cell proliferation (at DC: T cell ratios of 1:200) irrespective of whether these cells were activated with LPS or not. Similar results were obtained in two further independently performed MLRs from different donors with DC: T cell ratios of 1:2 and 1:20 (data not shown).
DISCUSSION
Dendritic cells play a central role in the initiation and coordination of the immune response to infectious agents and tumors. Their function is tightly controlled by the local environment via cytokine and chemokine signals. Here we show that the cytokine IL-6 strongly impairs CCR7 expression and chemotaxis in DC, which are required to recruit these cells to lymphoid tissues in vivo.
IL-6 has a decisive role in the fate of monocytes. These cells have the plasticity to differentiate into either macrophages or DC. IL-6 promotes macrophage generation (14-16, 32) similar to IL-10 (33, 34), even under conditions that normally favor DC development in vitro. We have confirmed and extended the findings of Mitani et al. (16) , which show that pro-inflammatory stimuli antagonize this IL-6 effect leading to an "intermediate phenotype". Our data demonstrate that stimulation of TLR4 by LPS re-directs the phenotype of monocytes to DC as judged by morphology and surface marker expression. This was observed even when the cells encountered LPS 6 days after the initial IL-6 trigger. To analyze the impact of IL-6 on DC maturation, the expression of various molecules typically associated with maturation were studied. Only expression of the surface molecule CD83 was partially reduced in several donors when IL-6 was added the first day of DC culture. CD40 and CD80 protein expression levels remained rather unchanged, whereas MHC class II, DC-LAMP, and CD86 were even up-regulated in IL-6-DC. This was in accordance with observations recently made in DC stimulated with IL-6 producing leukemia cells (11) . However, this contrasts previously described effects of IL-10. IL-10 strongly prevents LPS-mediated up-regulation of CD83 and of the co-stimulatory molecules CD80 and CD86 in DC (35, 36).
In vivo, LPS can trigger the egress of DC from non-lymphoid tissues (37). Mature DC follow a chemotactic gradient of SLC and ELC, which directs them to the peripheral lymphatic vessels and toward the T cell zones of the draining lymph nodes. This DC function can be studied in vitro by using transwell migration assays. We observed that IL-6 stimulation led to a reduced chemotactic response to the CCR7-activating chemokines ELC and SLC in LPS-matured DC. This functional defect was paralleled by a strong, IL-6-mediated inhibition of CCR7 upregulation at the protein and mRNA level. This result was surprising since CCR7 expression is thought to be tightly linked to maturation and the expression of other maturation markers (22, 23 ).
IL-6-mediated suppression of CCR7 expression was not restricted to LPS-matured DC. It was also observed when DC were activated with a TLR3 stimulus mimicking double-stranded RNA, or with TNF-α, although to a lesser extent, whereas CD40L-induced CCR7 expression was least affected. As demonstrated for LPS-matured DC, the strong CCR7 suppression only correlated with a reduction of CD83 levels, which, however, was much less pronounced. Impaired CCR7 up-regulation was even observed in DC from those donors where expression of all maturation markers, including CD83, was unaffected. These data indicated that IL-6 dissociates the regulation of CCR7 and most other maturation-associated molecules. These findings further extend previous observations that CCR7 expression may be independently regulated from other maturation associated molecules. It was shown that CCR7 may be expressed and active in Langerhans cells lacking co-stimulatory molecules (38).
At which regulatory step could IL-6 signals interfere with the signaling pathways induced by TLR stimulation or by other pro-inflammatory stimuli? From the above experiments it can be concluded that the LPS-induced signaling pathway responsible for CD86 expression is operational under the influence of IL-6, whereas another pathway responsible for CCR7 expression is impaired. Two major signaling pathways have been associated with DC development and maturation so far.
Factors of the NF-κB family, i.e., RelB, have been implicated in the development and survival of DC (39, 40). In particular, c-Rel is up-regulated during differentiation and maturation (41, 42). Yet, studies performed in double knockout mice showed that deficiency of NF-κB p50 and c-Rel did not impair expression of MHC Class II or co-stimulatory molecules (19) .
Several studies have reported a role for the p38 MAPK in DC maturation, a pathway often activated concomitantly to NF-κB (20, 43) . This kinase is involved in NF-κB recruitment to selected chromatin targets (44), making it difficult to distinguish the relative contribution of each single signaling event. Applying low concentrations of the inhibitor SB203580 to LPS-matured DC, MHC Class II, the co-stimulatory molecules, and to a lesser extent CD83 were shown to be up-regulated by the p38 MAPK (20, 43) . At high concentrations SB203580 also suppresses CCR7 expression (27). It is known, however, that SB203580 can also inhibit other kinases at higher concentrations (45, 46). The contribution of p38 MAPK inhibition to SB203580-mediated inhibition of cellular signaling has only recently been assessed by using an SB203580-resistant form of the kinase (47).
The fact that IL-6 did not only inhibit CCR7 expression but also the production of NF-κB-dependent factors, like TNF-α and IP-10, further pointed to the possibility that indeed NF-κB activation might be inhibited by IL-6 in DC. Furthermore, our data show that both the IKKinhibitor N-ACC (28), as well as the NF-κB inhibitor CAPE (29), suppressed LPS-mediated CCR7 expression, which supports an important role for NF-κB in LPS-induced CCR7 expression in DC. In fact, in IL-6-DC LPS-induced binding activities of NF-κB factors, including c-Rel, RelB, and the p65 subunit were strongly reduced, whereas phosphorylation of the p38 MAPK was rather enhanced. These results indicate that CCR7 expression is apparently sensitive to NF-κB activity, an observation that has already been made in Hodgkin's lymphoma cells (25) . IL-6 also reduced NF-κB binding activity induced by TNF-α or CD40L (data not shown). However, as deduced from CCR7 MFIs, CD40-induced CCR7 expression was affected to a much lesser extent than TLR-induced CCR7 induction. Thus, it is tempting to speculate that CD40 may use additional signaling pathways apart from NF-κB to induce CCR7 expression. However, future work will have to define whether TLR-and CD40L-induced signals lead to CCR7 induction differ quantitatively or qualitatively.
For CD83 expression both the NF-κB and p38 pathways may play a role, whereas CD86 may be predominantly under the control of the p38 kinase, thus not being suppressed but enhanced by IL-6.
It has been described that IL-10 does not only reduce NF-κB activation and binding activity in a monocytic cell line but also CCR7 expression in LPS-stimulated DC (48) (49) (50) . Both IL-6 and IL-10 share common signaling mechanisms that lead to STAT3 activation. They also show differences in signaling. IL-10 suppresses p38 MAPK activity in DC (51), whereas IL-6 does not. IL-10 has been shown to block IL-6 expression in LPS-matured DC (35), whereas IL-6 rather enhanced IL-10 levels in a mouse model (52) . We therefore investigated, whether IL-10 was involved in IL-6-mediated suppression of CCR7 expression. In fact, when DC were treated with IL-6 from the first day of culture, IL-10 was specifically induced in IL-6-DC after two days. Anti-IL-10 mAbs at doses that can neutralize high amounts of IL-10 partially restored LPSinduced CCR7 expression in IL-6-DC, indicating that this IL-6 effect is in part mediated via autocrine IL-10 production. When cells were stimulated with IL-6 at later time points (day 4), no autocrine IL-10 was detected, but CCR7 was still partially suppressed arguing for an additional, IL-10-independent component in IL-6-mediated CCR7 regulation. This has to be defined in the future. Furthermore, IL-6 and IL-10 do not have an identical immunosuppressive profile. Suppression of maturation-associated molecules observed with IL-10 may be overcome by signaling events specific to IL-6 or may require a higher autocrine IL-10 dose.
Recently, it has been shown that in the absence of suppressor of cytokine signaling 3 (SOCS3) IL-6 induces an anti-inflammatory response in macrophages (53) . Our data provide evidence that in cell types where IL-6 stimulates autocrine IL-10 production, IL-6 can also mediate anti-inflammatory effects. These responses may then become independent of SOCS3 expression levels, since SOCS3 does not inhibit IL-10 functions (53-55).
The presence of IL-6 in peripheral tissues has profound consequences for the nature of the immune response. IL-6 suppresses the production of pro-inflammatory cytokines and induces IL-1 receptor antagonist [reviewed in (9) ]. This study does not only add a novel IL-6-mediated immunosuppressive function but also provides a novel mechanism. In the presence of GM-CSF, IL-4, and a TLR stimulus or TNF-α, IL-6 skews monocyte differentiation into DC appearing phenotypically mature but being functionally impaired. These cells show reduced NF-κB activation and cannot up-regulate the chemokine receptor CCR7 during maturation. IL-6 might inhibit CCR7 expression in order to keep DC at the site of inflammation and thus present antigen at these sites. However, our data show that besides CCR7, IL-6 also impairs the production of pro-inflammatory mediators like TNF-α and IP-10 and even inhibits T cell proliferation arguing for a broad impairment of central DC functions.
From our data we conclude that assessing DC for maturation markers in vitro and most likely also in situ will not necessarily be predictive for the functional consequences of maturation, as these cells might have an impaired migration capacity.
As IL-6 is expressed in response to various pro-inflammatory stimuli in vivo, the mechanisms described here might contribute to an IL-6-mediated negative feedback and thereby to the downregulation of the immune response initiated by pathogens or in persistent infections involving TLR signals. Moreover, they may play a role also in malignant diseases in which IL-6 production is correlated with immune failure or a negative prognosis of disease progression (10, 11, 56, 57) . 1 . LPS counteracts the IL-6-mediated effect on monocyte differentiation (A). Human blood monocytes were cultured for 8 d with GM-CSF (100 ng/ml) and IL-4 (5 ng/ml), either in the absence (left panels) or presence of IL-6 (100 ng/ml, middle and right panels). On day 6, cells were stimulated with medium (upper panels) or LPS (250 ng/ml, lower panels). Surface expression of CD14 and CD1a was determined by flow cytometry. The IL-6 treated cells were visualized by phase contrast microscopy at 400× magnification (right panels). Shown is one representative experiment out of three independent experiments. Expression of maturation markers in IL-6-DC (B). Monocytes were cultured as above in the absence (upper and middle panels) or presence (lower panel) of 100 ng/ml IL-6. On day 6 they were stimulated with medium (upper panel) or LPS (250 ng/ml, middle and lower panels). After 48 h the cells were stained using specific mAbs directed against CD40, CD80, CD83, CD86, MHC class II, and DC-LAMP (solid lines) or respective isotype controls (dotted lines) and analyzed by flow cytometry. Shown are the results of a representative experiment out of three. were cultured with GM-CSF (100 ng/ml) and IL-4 (5 ng/ml) in the absence (empty bars) or presence (gray bars) of IL-6 (100 ng/ml). On day 6 the cells were stimulated with LPS (250 ng/ml) for 48 h. Migration of 5 × 10 5 DC toward 200 ng/ml SLC, 200 ng/ml ELC (left panel), or 100 ng/ml SDF-1α (right panel) was determined in a 4 h transwell chemotaxis assay. Data represent mean values (±SD) of triplicate determinations. Shown is one representative experiment out of three independent experiments. IL-6 inhibits LPS-induced up-regulation of CCR7 (B). Human blood monocytes were cultured with GM-CSF (100 ng/ml) and IL-4 (5 ng/ml) in the presence or absence of increasing doses of IL-6. On day 6, the cells were stimulated with medium (upper panel) or LPS (250 ng/ml, lower panel). After 48 h cells were stained with anti-CCR7 mAb (solid lines) or isotype-matched mAb (dotted lines) and were analyzed by flow cytometry. Shown is one out of three independently performed experiments. were cultured with GM-CSF (100 ng/ml) and IL-4 (5 ng/ml) in the presence or absence of IL-6 (100 ng/ml). Forty-eight hours after LPS treatment they were stained for CD83 (gray bars) and CCR7 (empty bars) surface expression. Shown are relative expression levels (MFIs) of IL-6-vs. medium-treated DC. IL-6 effect on poly (I:C)-, TNF-α-and CD40L-induced CCR7 expression (B). Monocytes were cultured as above in the presence (lower panels) or absence (upper panels) of IL-6 (100 ng/ml). On day 6, the cells were stimulated with poly (I:C) (200 µg/ml, left panels), TNF-α (5000 U/ml, middle panels), or paraformaldehyde-fixed BHK CD40L (3×10 6 /ml, right panels). Forty-eight hours later cells were stained with anti-CCR7 mAb (solid lines) or isotype-matched mAb (dotted lines) and were analyzed by flow cytometry. Shown is one out of three independently performed experiments. . Time kinetics of IL-6-mediated CCR7 suppression (A). Human blood monocytes were cultured with GM-CSF (100 ng/ml) and IL-4 (5 ng/ml). IL-6 (100 ng/ml) was added to the cultures at the indicated time points. On day 6 the cells were stimulated with medium (upper panel) or LPS (250 ng/ml, lower panel). After 48 h cells were stained for CCR7 expression (solid lines) or with isotype-matched mAb (dotted lines). Shown is one out of two independently performed experiments and corresponding MFIs (bottom panel). IL-6 regulates CCR7 expression at the mRNA level (B). Human blood monocytes were cultured for 7 days as above either in the absence (Lanes 1 and 3) or presence of IL-6 (100 ng/ml, Lanes 2 and 4). On day 6 they were stimulated with medium (Lanes 1 and 2) or LPS (250 ng/ml, Lanes 3 and 4). Total RNA was prepared after 24 h. Portions (5 µg) of each sample were investigated for CCR7 mRNA expression by RNase protection assay. GAPDH mRNA served as an internal control. Shown is one representative experiment out of five independent experiments (left panel) and corresponding aggregate data from all five experiments as determined by QuantifyOne ® 1-D analysis (right panel).
Fig. 5
Figure 5. p38 MAPK activationis not suppressed in IL-6-DC. Human blood monocytes were cultured with GM-CSF (100 ng/ml) and IL-4 (5 ng/ml) in the absence (Lanes 1, 3, 5, and 7) or presence of IL-6 (100 ng/ml, Lanes 2, 4, 6, and 8).
On day 6 the cells were stimulated with medium (Lanes 1 and 2) or LPS (250 ng/ml, Lanes 3-8) for the indicated time intervals. Whole cell extracts were prepared and analyzed by Western blot using phosphorylation-specific (top panel) or non-phosphorylation-specific Abs directed against the p38 MAPK (middle panel). Equal loading was controlled using a β-actin specific mAb (bottom panel). Shown is one out of two independently performed experiments. Figure 6 . IL-6 reduces LPS-induced IP-10 and TNF-α production (A). Human blood monocytes from four different donors were cultured with GM-CSF (100 ng/ml) and IL-4 (5 ng/ml) either in the absence or presence of IL-6 (100 ng/ml). On day 6, they were stimulated with medium or LPS (250 ng/ml). Twenty-four hours after LPS stimulation supernatants were harvested and analyzed for IP-10 and TNF-α levels (per 10 6 cells) by ELISA. N-ACC inhibits LPS-induced NF-κB binding activity (B). Human blood monocytes were cultured as described above. On day 6, they were incubated without (Lanes 1 and 2) or with N-ACC (25 mM; Lane 3) for 1 h and then stimulated with medium (Lane 1) or LPS (250 ng/ml, Lanes 2 and 3) for 1 h. Nuclear extracts were prepared and analyzed by EMSA using a 32 P-labeled NF-κB specific probe. N-ACC inhibits LPS-induced CCR7 induction (C). Cells from the same donor as shown in (A) were treated as described above. Forty-eight hours after LPS stimulation cells were stained for CCR7 expression (solid lines) or with isotypematched mAb (dotted lines). Shown is one out of three independently performed experiments. CAPE inhibits LPSinduced CCR7 induction (D). Human blood monocytes were cultured as described above. On day 6, they were incubated with medium, DMSO, or CAPE (25 or 50 µg/ml) for 2 h and then stimulated with or without LPS (250 ng/ml). Fortyeight hours after LPS stimulation cells were stained for CCR7 expression (solid lines) or with isotype-matched mAb (dotted lines). MFI values averaged from three different experiments are shown below. CCR7 expression of LPSstimulated cells without inhibitor or DMSO was set for 100%. 8 . IL-6-stimulated DC produce IL-10 (A). Human blood monocytes were cultured with GM-CSF (100 ng/ml) and IL-4 (5 ng/ml) either in the absence (not shown) or presence of IL-6 (100 ng/ml). After the indicated time points, IL-10 levels (per 10 6 cells) were determined in supernatants by ELISA. Anti-IL-10 partially neutralizes the IL-6 effect on CCR7 expression (B). Human blood monocytes were cultured as above in the absence (top histogram panels) or presence of IL-6 (100 ng/ml, middle histogram panels) or IL-10 (5 ng/ml, bottom histogram panels) and anti-IL-10 mAb (10 µg/ml, right panels), IgG2B isotype-matched control mAb (10 µg/ml, middle panels), or no Ab (left panels) for 8 d. Antibodies were added to the cultures each day. On day 6 the cells were stimulated with LPS (250 ng/ml). Forty-eight hours later CCR7 expression was assessed by flow cytometry and MFIs were determined. Shown is one out of two independently performed experiments. 9 . IL-6-conditioned DC display reduced allogeneic T cell stimulation capacity. DC were cultured in the presence or absence of 100 ng/ml IL-6 for 7 days. Within the last 16 h cells were treated with 250 ng/ml LPS or medium as control. CD4-positive, CD45R0-negative responder T cells were co-cultured in duplicates with these DC at the stimulator: responder ratio of 1:200 for 5 days. The percentage of CD3-stained cells having incorporated BrdU was determined by flow cytometry. Shown are the relative T helper cell proliferation rates of two independently performed MLRs.
